The Mexican Senate is getting ready to argue a policy that would legalize cannabis in the country.

Thanks to the alignment of the justice, health and legislative studies commissions in the Mexican Senate, the policy was approved and now heads to the Senate, where it will be discussed and reviewed.

The ruling from the three divisions was approved with a final vote of 26 compared to seven against while eight abstained on Wednesday (March 4).


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Luis Armendariz, a partner at CAAM Legal and a legal expert on the cannabis industry, told the Investing News Network (INN) that after an expected win for the bill at the next stage, it will take time for the industry to get going and for the creation of the agency tasked with regulating the market to be created. 

In an email response, Armendariz said he expects once Mexican businesses begin to obtain licenses and settle in the market, partnerships with international partners will begin to take form.

“There are Mexican business owners looking for foreign partners to commercialize their already existing products with brands in countries like US and Canada,” Armendariz said.

According to a report from El Universal, the eventual law would set up an entirely new policy to oversee the industry along with changes in the General Law on Health and the Federal Penal Code.

This potential bill, as currently constructed, would allow people to possess up to 28 grams of cannabis and institute a 12 percent suggested tax on all products.

Despite the anticipation and cultural impact attached to the legalization effort, some business minds are not thrilled about the current path of reform in Mexico. Alfredo Alvarez, a business partner of Mexican-based Canncura, told Marijuana Business Daily the policy as it stands would cause overregulation for licenses and limit business integration.

Armendariz agrees with the sentiment that the current policy is too restrictive for businesses. However, he told INN this is still a massive step for the country and its relationship with the drug.

It’s been a long road for the country ever since the government of Mexican President Andres Manuel Lopez Obrador hinted at its interest in working out a cannabis policy.

The Mexican government is facing a deadline of April 30 for the legalization of the drug as part of a Supreme Court ruling in the country.

Armendariz told INN he is fully expecting the legalization process to be completed before the deadline given that in his opinion the biggest obstacle for the policy was guaranteeing an agreement between the political parties to put the bill forward for a vote. Given that the ruling party, MORENA, is also in control of the Chamber of Deputies, the expert doesn’t expect a problem with the passing of the motion.

However, despite the interest in the legalization process for the drug, Lopez Obrador threw a curveball at the entire path ahead for the drug after he claimed to support only medical use. A report from The Yucatan Times indicated as part of his daily press remarks, the Mexican president showed his disdain for recreational drug use with a video presentation.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here:

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less